| Ytd | 240.34% | |
| 1y | 240.34% |
| Open | 122.13 | Prev Close | 122.94 | Low | 120.00 | High | 131.24 | Mkt Cap | 5.37B |
| Vol | 530.82K | Avg Vol | 660.80K | EPS | -2.65 | P/E | N/A | Forward P/E | -40.39 |
| Beta | N/A | Short Ratio | 5.52 | Inst. Own | 79.84% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 101.09 | 200-d Avg | 77.49 | 1yr Est | 132.80 |
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs
LifeSci Capital analyst Rami Katkhuda initiates coverage on Veradermics (NYSE:MANE) with a Outper
Wall Street analysts changed outlook on top names: ODTX, MOBI, MANE. See analyst ratings page for al
Needham analyst Serge Belanger initiates coverage on Veradermics (NYSE:MANE) with a Buy rating an